Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers
Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers
复制标题
DOI：
10.1016/j.leukres.2005.03.019
复制
发表时间：
2005-10-01
影响因子：
2.7
通讯作者：
Fichtner, I
中科院分区：
文献类型：
--
作者：
Henschler, R;Göttig, S;Fichtner, I
为了更好地表征非肥胖糖尿病(NOD)/严重联合免疫缺陷（SCID）小鼠的急性髓性白血病（AML）发展，我们移植了AML患者或KG-1和EOL-1细胞系的样本。我们发现9/12的原发性AML样本和两种细胞系在2-8周内移植，骨髓中有5-80%的人细胞。与新分离的AML细胞相比，移植后人类CD33（+）、CD38（+）、CD31（+）、CD13（+）或CD15（+）亚群的百分比增加，而CD34（+）细胞的百分比下降。移植小鼠经常表达人内皮细胞标记物。因此，将人AML移植到NOD/SCID小鼠体内可以发现造血和内皮分化标志物的表达。(c) 2005 Elsevier Ltd版权所有。
To better characterize acute myeloid leukemia (AML) development in non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice, we transplanted samples from patients with AML or KG-1 and EOL-1 cell lines. We found 9/12 primary AML samples and both cell lines to engraft within 2-8 weeks, with 5-80% human cells in bone marrow. Compared with freshly isolated AML cells, percentages of human CD33(+), CD38(+), CD31(+) CD13(+) or CD15(+) subpopulations increased after transplantation, whereas percentages of CD34(+) cells decreased. Engrafted mice frequently showed expression of human endothelial cell markers. Thus, transplantation of human AML into NOD/SCID mice reveals expression of hematopoietic and endothelial differentiation markers. (c) 2005 Elsevier Ltd. All rights reserved.